PRINCIPAL ACTIVITY BARD1 Life Sciences Limited (BD1, formerly Eurogold Limited) is a Swiss public company limited by shares that has pioneered, through the development of theBARD1AG Intellectual Property, a simple blood test for screening and diagnosing lung cancer at early stages of disease progression.
PORTFOLIO: The company's portfolio includes an exclusive and worldwide license from UNIGE / HUG for PCT/IB2011/053635 filed on 17 August 2011 (WO 2012/023112) for BARD1 isoforms in lung and colorectal cancer and use thereof, I Irminger Finger and YQ Zhang (Hopitaux Universitaires de Geneve and University of Geneva) as well as any future related patent application or extension (BARD1AG IP Licence).
BARD1 Life Sciences Ltd (ASX: BD1) is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer. The BARD1 technology platform includes proprietary, proven and specific cancer biomarkers, diagnostic algorithms and assays. Its lead product the BARD1 Lung Cancer Test is a non-invasive blood test in development for early detection of lung cancer. It is also researching a high-value pipeline of potential diagnostic and therapeutic products for multiple cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.
SHAREHOLDER UPDATE
Australian biotechnology company BARD1 Life Sciences Limited (ASX: BD1) ( BARD1 LSL or the Company ) provides the following shareholder update on the status of its Lung Cancer diagnostics program. BARD1 LSL initiated a 450 - subject lung cancer study in late 2016 to evaluate the feasibility of its research - grade BARD1 Lung Cancer Test on the Meso Scale Diagnostics ( MSD ) research - use - only ( RUO ) instrument platform, and its performance characteristics across different lung cancer sub types and stages . The initial results of the pilot study to set up the BARD1 Lung Cancer Test used 40 samples (20 lung cancer and 20 controls) on the MSD RUO instrument platform and yielded a receiver operating characteristic (ROC ) - area under the curve (AUC) = 0.93 , thus verifying the reproducibility of the test in this setting (see ASX announcement of 8/2/17). The Company had previously advised that it had expected to announce the results of its lung cancer study to optimise the performance and determine the limits of the test for detection of lung cancers by the end of March 2017.
However, due to the expanded study testing 638 subjects across a broad range of lung cancer subtypes, stages and origins , the data is still undergoing analysis and external expert review to finalise the results, and determine the performance of the BARD1 Test for early detection of lung cancer . The Company will now report the results to the market once this analysis is completed and the final report is available. This process is expected to take up to 8 weeks. The BARD1 Lung Cancer Test is an ELISA - based blood test in development for the screening and diagnosis of lung cancer. The test measures multiple BARD1 autoantibodies, and uses a proprietary diagnostic algorithm to identify the presence or absence of lung cancer
